Robert Jones, MD, PhD, University of Glasgow & Beatson West of Scotland Cancer Centre, Glasgow, UK, discusses recent updates in prostate cancer. Prof. Jones highlights data coming from a number of Phase III trials including the STAMPEDE (NCT00268476), VISION (NCT03511664) and PROfound (NCT02987543) studies. The STAMPEDE study assessed abiraterone acetate plus prednisolone with or without enzalutamide added to androgen deprivation therapy (ADT) compared to ADT alone for men with high-risk non-metastatic prostate cancer. The VISION study compared best standard of care (BSOC) and 177Lu-PSMA-617, and the PROfound trial evaluated olaparib – both in patients with metastatic castration-resistant prostate cancer (mCRPC). Prof. Jones reviews the data coming from these studies, and the impact of these data on clinical practice. This interview took place at the BOPA 2021 virtual meeting.